{"gene":"HAS1","run_date":"2026-04-28T18:06:53","timeline":{"discoveries":[{"year":2000,"finding":"HAS1 protein alone is sufficient to synthesize hyaluronan in vitro; the purified, FLAG-tagged HAS1 from membrane fractions synthesizes hyaluronan from UDP-GlcNAc and UDP-GlcA without additional cofactors. Site-directed mutagenesis of conserved residues in the cytoplasmic central loop domain identified distinct amino acid residues essential for GlcNAc and GlcA transfer, respectively. Additionally, HAS1 can synthesize chito-oligosaccharide when incubated with UDP-GlcNAc alone, with one residue required for hyaluronan but not chito-oligosaccharide synthesis.","method":"Recombinant protein purification, in vitro enzymatic assay, site-directed mutagenesis, in vitro transcription/translation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstituted in vitro activity with purified single protein, active-site mutagenesis with kinetic characterization","pmids":["10617644"],"is_preprint":false},{"year":2013,"finding":"HAS1 requires a substantially higher cellular concentration of UDP-GlcNAc than HAS2 or HAS3 to synthesize hyaluronan. In COS-1 cells, HAS1 is nearly inactive at basal UDP-sugar levels but produces hyaluronan when UDP-GlcNAc is elevated ~10-fold by glucosamine supplementation, indicating HAS1 has the lowest substrate affinity among the three isoenzymes.","method":"Transfection of HAS isoenzymes in COS-1 cells, glucosamine supplementation, UDP-sugar quantification, hyaluronan secretion assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal approaches (substrate supplementation, glucose deprivation, comparison across cell types) in single study","pmids":["23303191"],"is_preprint":false},{"year":2015,"finding":"HAS1, HAS2, and HAS3 form homomeric and heteromeric complexes with each other in live cells, detected in both Golgi apparatus and plasma membrane. These interactions occur primarily via the N-terminal 86-amino acid domain, with additional binding sites in C-terminal parts. HAS1 transfection reduces hyaluronan synthesis driven by HAS2 and HAS3, indicating functional cooperation. Of all homomeric complexes, HAS1 has the lowest synthetic activity.","method":"FRET in live cells, acceptor photobleaching FRET microscopy, proximity ligation assay with endogenous HAS antibodies, C-terminal deletion constructs","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — reciprocal FRET and proximity ligation with endogenous proteins, domain-deletion mapping, functional consequence measured","pmids":["25795779"],"is_preprint":false},{"year":2013,"finding":"HAS1-dependent hyaluronan coat formation on MCF-7 cell surfaces is induced by inflammatory cytokines (IL-1β, TNF-α, TGF-β) and glycemic stress (high glucose + glucosamine), and is dependent on CD44 receptor (coat removed by HA hexasaccharides or anti-CD44 antibody Hermes1). HAS1 enzymatic activity requires ER-Golgi-plasma membrane trafficking.","method":"Transfection of fluorescently tagged HAS1, immunocytochemistry, hyaluronan binding probe, hyaluronan hexasaccharide displacement assay, anti-CD44 antibody blocking","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 — direct localization and functional blocking experiments, single lab study","pmids":["24099991"],"is_preprint":false},{"year":2003,"finding":"IL-1β-induced HAS1 transcription in fibroblast-like synoviocytes depends on the p38 MAPK signaling pathway; hydrocortisone blocks TGF-β-induced HAS1 activation by inhibiting TGF-β-induced phosphorylation of p38 MAPK, as confirmed by Western blot. HAS1 (unlike HAS2/HAS3) is not constitutively expressed in these cells but is inducible by TGF-β and inflammatory stimuli.","method":"RT-PCR, Western blot for p38 MAPK phosphorylation, pharmacological inhibition with hydrocortisone/dexamethasone","journal":"Rheumatology (Oxford, England)","confidence":"Medium","confidence_rationale":"Tier 2 — Western blot mechanistic link between hydrocortisone and p38 MAPK blocking HAS1, single lab","pmids":["13130151"],"is_preprint":false},{"year":2005,"finding":"IL-1β activates HAS1 transcription via the NF-κB pathway in fibroblast-like synoviocytes, while TGF-β1 activates HAS1 independently of NF-κB. Overexpression of IκBα or dominant-negative IKK completely abolished IL-1β-induced HAS1 mRNA accumulation but did not affect TGF-β1-induced HAS1 or constitutive HAS2/HAS3 expression.","method":"Adenovirus-mediated gene transfer of mutated IKK and IκBα, RT-PCR, EMSA for NF-κB translocation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — adenoviral overexpression of dominant-negative constructs with multiple pathway readouts, two distinct stimuli compared","pmids":["16258173"],"is_preprint":false},{"year":2005,"finding":"IL-1β-induced HAS1 activation in fibroblast-like synoviocytes depends on tyrosine kinase activity (not NF-κB), as leflunomide blocks IL-1β-induced HAS1 mRNA induction without interfering with NF-κB translocation (EMSA), and two tyrosine kinase inhibitors phenocopied leflunomide's selective block of HAS1 without affecting HAS2 or HAS3.","method":"RT-PCR, 14C-glucuronic acid incorporation assay, EMSA, pharmacological inhibitors (leflunomide, tyrosine kinase inhibitors), pyrimidine rescue experiments","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — enzymatic assay plus EMSA and multiple pharmacological tools converging on tyrosine kinase requirement, single lab","pmids":["15905585"],"is_preprint":false},{"year":2008,"finding":"Epstein-Barr virus specifically induces HAS1 mRNA and hyaluronan synthesis in fibroblast-like synoviocytes, with HAS2 and HAS3 unchanged. This virus-induced HAS1 activation requires both p38 MAPK and NF-κB pathways, demonstrated using chemical inhibitors of MAPK and adenoviral overexpression of mutated IKK and IκBα.","method":"Real-time RT-PCR, adenoviral dominant-negative constructs for IKK/IκBα, MAPK inhibitors, HA secretion assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — pathway placement by dominant-negative constructs and pharmacological inhibition, single lab","pmids":["18400745"],"is_preprint":false},{"year":2009,"finding":"HAS1 splice variants (Va, Vb, Vc) form heteromeric multiprotein assemblies with full-length HAS1 and with each other, relocalizing HAS1-FL from diffuse cytoskeletal-anchored locations to deeper cytoplasmic/Golgi spaces and protecting HAS1-FL from rapid turnover. HAS1-Vs synthesize HA intracellularly, and HAS1-Vc is transforming in vitro and tumorigenic in vivo as a single oncogene.","method":"Co-transfection, co-immunoprecipitation, subcellular localization by immunofluorescence, in vitro transformation assay, mouse xenograft tumorigenicity assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2-3 — Co-IP for complex formation, multiple functional assays including in vivo tumorigenicity, single lab","pmids":["19451652"],"is_preprint":false},{"year":2015,"finding":"Deficiency of Has1 in mice results in chronic joint inflammation and widespread intra-articular fibrosis following cartilage injury, with sustained elevated expression of genes in IL-17/IL-6 cytokine signaling, ECM turnover, and apoptosis pathways. Notably, Has1 ablation does not alter gross HA content in the ECM, suggesting HAS1 has a unique function in inflammatory HA matrix metabolism distinct from bulk HA production.","method":"Has1 knockout mouse model, cartilage debridement injury, histology, macroscopic imaging, gene expression analysis","journal":"Osteoarthritis and cartilage","confidence":"Medium","confidence_rationale":"Tier 2 — clean KO with defined cellular and molecular phenotype, multiple readouts, single lab","pmids":["26521733"],"is_preprint":false},{"year":2024,"finding":"Phosphorylated tau mediates AβPP-induced cytosolic-to-nuclear translocation of HAS1. P-tau negatively regulates HAS1 stability, monoubiquitination, and oligomerization, reducing HA synthesis and release. Non-ubiquitinated HAS1 loses enzymatic activity and translocates to the nucleus, forming nuclear speckles with a regulatory role in gene transcription.","method":"AβPP/PS1 mouse model, cell transfection, immunofluorescence localization, ubiquitination assays, HAS1 mutant (non-ubiquitinatable) functional analysis, transcriptomic analysis","journal":"Matrix biology","confidence":"Medium","confidence_rationale":"Tier 2-3 — multiple methods including mutant analysis and mouse model, single lab, novel finding","pmids":["38518923"],"is_preprint":false},{"year":2026,"finding":"AMPK physically interacts with HAS1 to form a complex in hepatocytes; disruption of this AMPK/Has1 interaction by elemicin ameliorates hepatic steatosis, inflammation, and fibrosis in MASH mice. Liver-specific inhibition of Has1 alone also ameliorates MASH phenotypes in vivo and in vitro.","method":"Co-IP, SPR binding assay, CETSA, loss-of-function (liver-specific Has1 inhibition), HFHC diet MASH mouse model, transcriptomic and lipidomic analyses","journal":"Theranostics","confidence":"Medium","confidence_rationale":"Tier 2 — SPR and CETSA confirm direct AMPK-Has1 interaction, loss-of-function in vivo, single lab","pmids":["41695466"],"is_preprint":false},{"year":2020,"finding":"STAT3 directly binds to the HAS1 promoter region to regulate HAS1 transcription in non-small cell lung cancer cells; miR-125a suppresses STAT3 expression (validated by dual-luciferase reporter assay), which in turn reduces HAS1 expression at both mRNA and protein levels.","method":"Chromatin immunoprecipitation (ChIP) assay, dual-luciferase reporter assay, RT-qPCR, Western blot, miRNA overexpression","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP confirms STAT3 binding to HAS1 promoter, luciferase confirms miR-125a targeting STAT3, single lab","pmids":["31930562"],"is_preprint":false}],"current_model":"HAS1 is a plasma membrane-localized hyaluronan synthase that alone can synthesize hyaluronan from UDP-GlcNAc and UDP-GlcA via conserved cytoplasmic loop residues, requires higher substrate (UDP-GlcNAc) concentrations than HAS2/HAS3, forms homo- and heteromeric complexes with other HAS isoenzymes primarily through its N-terminal domain to functionally modulate total HA output, is transcriptionally activated by IL-1β via NF-κB and by TGF-β via NF-κB-independent pathways (both requiring p38 MAPK), is regulated by STAT3 binding to its promoter, physically interacts with AMPK in hepatocytes, and undergoes ubiquitination-dependent control of its enzymatic activity and subcellular localization (including p-tau-induced nuclear translocation in Alzheimer's disease context)."},"narrative":{"teleology":[{"year":2000,"claim":"Establishing that HAS1 alone is sufficient for hyaluronan synthesis resolved whether the enzyme requires cofactors or additional subunits, and mutagenesis of the central cytoplasmic loop identified distinct residues for GlcNAc and GlcA transfer, defining a two-site catalytic mechanism.","evidence":"Purified recombinant FLAG-HAS1 reconstituted in vitro; site-directed mutagenesis with kinetic assays","pmids":["10617644"],"confidence":"High","gaps":["No structural model of the active site or polymer translocation mechanism","Chito-oligosaccharide synthesis activity observed in vitro but physiological relevance unknown","Lipid/membrane dependence of activity not dissected"]},{"year":2003,"claim":"Identifying p38 MAPK as required for both IL-1β- and TGF-β-induced HAS1 transcription placed the gene under inflammatory signaling control and explained how glucocorticoids selectively suppress HAS1 without affecting HAS2/HAS3.","evidence":"RT-PCR and Western blot for p38 phosphorylation in fibroblast-like synoviocytes treated with hydrocortisone and pathway inhibitors","pmids":["13130151"],"confidence":"Medium","gaps":["Precise p38 MAPK targets on HAS1 promoter not mapped","Glucocorticoid receptor mechanism of p38 inhibition not resolved"]},{"year":2005,"claim":"Demonstrating that IL-1β induces HAS1 via NF-κB whereas TGF-β1 does so independently of NF-κB established that two major inflammatory pathways converge on HAS1 through distinct transcriptional mechanisms, and an additional tyrosine kinase requirement for IL-1β-driven HAS1 was identified.","evidence":"Adenoviral dominant-negative IKK/IκBα, EMSA, tyrosine kinase inhibitors in fibroblast-like synoviocytes","pmids":["16258173","15905585"],"confidence":"High","gaps":["Identity of the required tyrosine kinase not determined","Promoter elements mediating NF-κB versus TGF-β responses not mapped"]},{"year":2008,"claim":"Showing that Epstein-Barr virus selectively induces HAS1 (not HAS2/HAS3) through both p38 MAPK and NF-κB extended the inflammatory induction paradigm to viral stimuli and reinforced HAS1's role as the inducible isoenzyme.","evidence":"Real-time RT-PCR, dominant-negative IKK/IκBα adenoviral constructs, MAPK inhibitors, HA secretion assay in synoviocytes","pmids":["18400745"],"confidence":"Medium","gaps":["Viral component(s) triggering HAS1 induction not identified","Physiological consequence of virus-induced HAS1 on HA matrix not tested in vivo"]},{"year":2009,"claim":"Discovery that HAS1 splice variants form heteromeric complexes with full-length HAS1, alter its subcellular localization, protect it from degradation, and that one variant (HAS1-Vc) acts as a single oncogene revealed a layer of post-transcriptional regulation with direct disease relevance.","evidence":"Co-IP, immunofluorescence, in vitro transformation assay, mouse xenograft tumorigenicity","pmids":["19451652"],"confidence":"Medium","gaps":["Mechanism of HAS1-Vc oncogenic activity not elucidated","Endogenous expression levels and splicing regulation of HAS1 variants poorly characterized","Not independently replicated in a second laboratory"]},{"year":2013,"claim":"Quantifying HAS1's requirement for ~10-fold higher UDP-GlcNAc than HAS2/HAS3 explained why HAS1 is nearly inactive under basal metabolic conditions and linked its activity to nutrient/glycemic status.","evidence":"HAS isoenzyme transfection in COS-1 cells with glucosamine supplementation and UDP-sugar quantification","pmids":["23303191"],"confidence":"High","gaps":["Km values for purified HAS1 versus HAS2/HAS3 not compared in a cell-free system","Structural basis for differential substrate affinity unknown"]},{"year":2015,"claim":"FRET and proximity ligation demonstrated that HAS1 forms homo- and heteromeric complexes with HAS2/HAS3 at the plasma membrane and Golgi, primarily via the N-terminal 86 residues, and that HAS1 reduces HAS2/HAS3-driven HA synthesis, establishing oligomerization as a mechanism for tuning total HA output.","evidence":"Acceptor photobleaching FRET, proximity ligation assay with endogenous antibodies, C-terminal deletion mapping in live cells","pmids":["25795779"],"confidence":"High","gaps":["Stoichiometry and structural basis of HAS oligomers unresolved","Whether heteromeric complexes form in all tissue contexts unknown"]},{"year":2015,"claim":"Has1 knockout mice developed chronic joint inflammation and fibrosis after cartilage injury without changes in bulk HA content, revealing a unique role for HAS1 in inflammatory matrix homeostasis distinct from overall HA production.","evidence":"Has1 KO mouse, cartilage debridement injury, histology, gene expression profiling","pmids":["26521733"],"confidence":"Medium","gaps":["Whether the phenotype is due to loss of specific HA size classes or non-HA functions of HAS1 is unknown","Has1/Has2 or Has1/Has3 double knockout not examined"]},{"year":2020,"claim":"ChIP confirmation that STAT3 directly binds the HAS1 promoter added a third transcription factor (beyond NF-κB and p38-dependent factors) to HAS1 regulation and connected HAS1 to oncogenic STAT3 signaling in lung cancer.","evidence":"ChIP assay, dual-luciferase reporter for miR-125a–STAT3 axis, RT-qPCR and Western blot in NSCLC cells","pmids":["31930562"],"confidence":"Medium","gaps":["Specific STAT3 binding site on HAS1 promoter not mapped at base-pair resolution","Functional consequence of STAT3-driven HAS1 on HA synthesis in lung cancer not quantified"]},{"year":2024,"claim":"Demonstrating that phosphorylated tau destabilizes HAS1 monoubiquitination, abolishes enzymatic activity, and triggers cytosol-to-nuclear translocation where HAS1 forms nuclear speckles with transcriptional regulatory capacity revealed a non-canonical nuclear function for HAS1 in the Alzheimer's disease context.","evidence":"AβPP/PS1 mouse model, ubiquitination assays, non-ubiquitinatable HAS1 mutants, immunofluorescence, transcriptomics","pmids":["38518923"],"confidence":"Medium","gaps":["Target genes regulated by nuclear HAS1 not defined","Whether nuclear HAS1 retains any enzymatic activity is untested","Findings from a single laboratory and not yet independently confirmed"]},{"year":2026,"claim":"Identification of a direct physical AMPK–HAS1 interaction in hepatocytes, whose disruption ameliorates MASH, revealed HAS1 as a metabolic effector in the liver linking HA metabolism to steatosis and fibrosis.","evidence":"Co-IP, SPR, CETSA for direct binding; liver-specific Has1 inhibition in HFHC diet MASH mouse model","pmids":["41695466"],"confidence":"Medium","gaps":["Whether AMPK phosphorylates HAS1 or modulates its activity directly is unknown","Mechanism by which HAS1 promotes hepatic steatosis and fibrosis not fully elucidated","Single laboratory finding requiring independent replication"]},{"year":null,"claim":"Key unresolved questions include the structural basis for HAS1's low substrate affinity, the identity of target genes regulated by nuclear HAS1, the molecular mechanism by which ubiquitination controls HAS1 localization and activity, and whether HAS1's role in joint inflammation reflects production of specific HA size classes or non-enzymatic functions.","evidence":"","pmids":[],"confidence":"High","gaps":["No crystal or cryo-EM structure of any HAS isoenzyme","Nuclear HAS1 transcriptional targets undefined","HA size-class specificity of HAS1 versus HAS2/HAS3 not resolved in vivo"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,1]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[10]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[2,3]},{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[2,8]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[10]}],"pathway":[{"term_id":"R-HSA-1474244","term_label":"Extracellular matrix organization","supporting_discovery_ids":[0,1,9]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[5,7,12]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[5,7]}],"complexes":["HAS homo/heteromeric complexes (HAS1–HAS1, HAS1–HAS2, HAS1–HAS3)"],"partners":["HAS2","HAS3","STAT3","PRKAA1"],"other_free_text":[]},"mechanistic_narrative":"HAS1 is a hyaluronan synthase that catalyzes the polymerization of hyaluronan from UDP-GlcNAc and UDP-GlcA at the plasma membrane, operating with lower substrate affinity than the paralogous enzymes HAS2 and HAS3 and thus functioning primarily under conditions of elevated UDP-sugar availability [PMID:10617644, PMID:23303191]. HAS1 forms homo- and heteromeric complexes with other HAS isoenzymes through its N-terminal domain, modulating total hyaluronan output, and its enzymatic activity is controlled by monoubiquitination, the loss of which triggers nuclear translocation and transcriptional regulatory functions [PMID:25795779, PMID:38518923]. Transcription of HAS1 is inducible rather than constitutive: IL-1β activates HAS1 via NF-κB and p38 MAPK, TGF-β acts through p38 MAPK independently of NF-κB, and STAT3 directly binds the HAS1 promoter [PMID:16258173, PMID:13130151, PMID:31930562]. In vivo, Has1 deficiency causes chronic joint inflammation and fibrosis following cartilage injury without altering bulk hyaluronan content, indicating a specialized role in inflammatory extracellular matrix homeostasis distinct from bulk hyaluronan production [PMID:26521733]."},"prefetch_data":{"uniprot":{"accession":"Q92839","full_name":"Hyaluronan synthase 1","aliases":["Hyaluronate synthase 1","Hyaluronic acid synthase 1","HA synthase 1","HuHAS1"],"length_aa":577,"mass_kda":64.7,"function":"Catalyzes the addition of GlcNAc or GlcUA monosaccharides to the nascent hyaluronan polymer. Therefore, it is essential for the synthesis of hyaluronan, a major component of most extracellular matrices that has a structural role in tissue architecture and regulates cell adhesion, migration and differentiation. This is one of the isozymes catalyzing that reaction. Also able to catalyze the synthesis of chito-oligosaccharide depending on the substrate (By similarity)","subcellular_location":"Membrane","url":"https://www.uniprot.org/uniprotkb/Q92839/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/HAS1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/HAS1","total_profiled":1310},"omim":[{"mim_id":"602428","title":"HYALURONAN SYNTHASE 3; HAS3","url":"https://www.omim.org/entry/602428"},{"mim_id":"601636","title":"HYALURONAN SYNTHASE 2; HAS2","url":"https://www.omim.org/entry/601636"},{"mim_id":"601463","title":"HYALURONAN SYNTHASE 1; HAS1","url":"https://www.omim.org/entry/601463"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"},{"location":"Nucleoplasm","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"adipose tissue","ntpm":46.2},{"tissue":"ovary","ntpm":19.3}],"url":"https://www.proteinatlas.org/search/HAS1"},"hgnc":{"alias_symbol":[],"prev_symbol":["HAS"]},"alphafold":{"accession":"Q92839","domains":[{"cath_id":"3.90.550.10","chopping":"96-168_193-396","consensus_level":"medium","plddt":95.6638,"start":96,"end":396}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q92839","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q92839-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q92839-F1-predicted_aligned_error_v6.png","plddt_mean":88.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=HAS1","jax_strain_url":"https://www.jax.org/strain/search?query=HAS1"},"sequence":{"accession":"Q92839","fasta_url":"https://rest.uniprot.org/uniprotkb/Q92839.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q92839/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q92839"}},"corpus_meta":[{"pmid":"24337597","id":"PMC_24337597","title":"Hyaluronan synthases (HAS1-3) in stromal and malignant cells correlate with breast cancer grade and predict patient survival.","date":"2013","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/24337597","citation_count":114,"is_preprint":false},{"pmid":"10617644","id":"PMC_10617644","title":"In vitro synthesis of hyaluronan by a single protein derived from mouse HAS1 gene and characterization of amino acid residues essential for the activity.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10617644","citation_count":101,"is_preprint":false},{"pmid":"23303191","id":"PMC_23303191","title":"Hyaluronan synthase 1 (HAS1) requires higher cellular UDP-GlcNAc concentration than HAS2 and HAS3.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23303191","citation_count":96,"is_preprint":false},{"pmid":"22785117","id":"PMC_22785117","title":"Hyaluronic acid, HAS1, and HAS2 are significantly upregulated during muscle hypertrophy.","date":"2012","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/22785117","citation_count":62,"is_preprint":false},{"pmid":"20875124","id":"PMC_20875124","title":"Hyaluronan synthases (HAS1-3) and hyaluronidases (HYAL1-2) in the accumulation of hyaluronan in endometrioid endometrial carcinoma.","date":"2010","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/20875124","citation_count":55,"is_preprint":false},{"pmid":"15731173","id":"PMC_15731173","title":"Intronic splicing of hyaluronan synthase 1 (HAS1): a biologically relevant indicator of poor outcome in multiple myeloma.","date":"2005","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15731173","citation_count":54,"is_preprint":false},{"pmid":"12239172","id":"PMC_12239172","title":"Characterization of hyaluronan synthase expression and hyaluronan synthesis in bone marrow mesenchymal progenitor cells: predominant expression of HAS1 mRNA and up-regulated hyaluronan synthesis in bone marrow cells derived from multiple myeloma patients.","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12239172","citation_count":53,"is_preprint":false},{"pmid":"23788678","id":"PMC_23788678","title":"Has1 regulates consecutive maturation and processing steps for assembly of 60S ribosomal subunits.","date":"2013","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/23788678","citation_count":51,"is_preprint":false},{"pmid":"24406795","id":"PMC_24406795","title":"Extensive CD44-dependent hyaluronan coats on human bone marrow-derived mesenchymal stem cells produced by hyaluronan synthases HAS1, HAS2 and HAS3.","date":"2014","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/24406795","citation_count":49,"is_preprint":false},{"pmid":"19435493","id":"PMC_19435493","title":"Expression of hyaluronan synthases (HAS1-3) and hyaluronidases (HYAL1-2) in serous ovarian carcinomas: inverse correlation between HYAL1 and hyaluronan content.","date":"2009","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19435493","citation_count":49,"is_preprint":false},{"pmid":"26521733","id":"PMC_26521733","title":"Deficiency of hyaluronan synthase 1 (Has1) results in chronic joint inflammation and widespread intra-articular fibrosis in a murine model of knee joint cartilage damage.","date":"2015","source":"Osteoarthritis and cartilage","url":"https://pubmed.ncbi.nlm.nih.gov/26521733","citation_count":42,"is_preprint":false},{"pmid":"17230515","id":"PMC_17230515","title":"HAS1 expression in bladder cancer and its relation to urinary HA test.","date":"2007","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17230515","citation_count":41,"is_preprint":false},{"pmid":"23645665","id":"PMC_23645665","title":"Low dose ultraviolet B irradiation increases hyaluronan synthesis in epidermal keratinocytes via sequential induction of hyaluronan synthases Has1-3 mediated by p38 and Ca2+/calmodulin-dependent protein kinase II (CaMKII) signaling.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23645665","citation_count":38,"is_preprint":false},{"pmid":"25795779","id":"PMC_25795779","title":"Fluorescence resonance energy transfer (FRET) and proximity ligation assays reveal functionally relevant homo- and heteromeric complexes among hyaluronan synthases HAS1, HAS2, and HAS3.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25795779","citation_count":36,"is_preprint":false},{"pmid":"24099991","id":"PMC_24099991","title":"Hyaluronan synthase 1 (HAS1) produces a cytokine-and glucose-inducible, CD44-dependent cell surface coat.","date":"2013","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/24099991","citation_count":31,"is_preprint":false},{"pmid":"15246064","id":"PMC_15246064","title":"Light and metabolic regulation of HAS1, HAS1.1 and HAS2, three asparagine synthetase genes in Helianthus annuus.","date":"2004","source":"Plant physiology and biochemistry : PPB","url":"https://pubmed.ncbi.nlm.nih.gov/15246064","citation_count":30,"is_preprint":false},{"pmid":"13130151","id":"PMC_13130151","title":"Glucocorticoids inhibit induced and non-induced mRNA accumulation of genes encoding hyaluronan synthases (HAS): hydrocortisone inhibits HAS1 activation by blocking the p38 mitogen-activated protein kinase signalling pathway.","date":"2003","source":"Rheumatology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/13130151","citation_count":26,"is_preprint":false},{"pmid":"19451652","id":"PMC_19451652","title":"Aberrant splice variants of HAS1 (Hyaluronan Synthase 1) multimerize with and modulate normally spliced HAS1 protein: a potential mechanism promoting human cancer.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19451652","citation_count":24,"is_preprint":false},{"pmid":"18815290","id":"PMC_18815290","title":"Inherited and acquired variations in the hyaluronan synthase 1 (HAS1) gene may contribute to disease progression in multiple myeloma and Waldenstrom macroglobulinemia.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18815290","citation_count":21,"is_preprint":false},{"pmid":"33908161","id":"PMC_33908161","title":"Hyaluronic acid (HA) stimulates the in vitro expression of CD44 proteins but not HAS1 proteins in normal human epidermal keratinocytes (NHEKs) and is HA molecular weight dependent.","date":"2021","source":"Journal of cosmetic dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/33908161","citation_count":19,"is_preprint":false},{"pmid":"15905585","id":"PMC_15905585","title":"Effects of leflunomide on hyaluronan synthases (HAS): NF-kappa B-independent suppression of IL-1-induced HAS1 transcription by leflunomide.","date":"2005","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15905585","citation_count":19,"is_preprint":false},{"pmid":"23149717","id":"PMC_23149717","title":"Lentiviral-mediated over-expression of hyaluronan synthase-1 (HAS-1) decreases the cellular inflammatory response and results in regenerative wound repair.","date":"2012","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/23149717","citation_count":18,"is_preprint":false},{"pmid":"16723203","id":"PMC_16723203","title":"The NF-kappaB inhibitor pyrrolidine dithiocarbamate blocks IL-1beta induced hyaluronan synthase 1 (HAS1) mRNA transcription, pointing at NF-kappaB dependence of the gene HAS1.","date":"2006","source":"Experimental gerontology","url":"https://pubmed.ncbi.nlm.nih.gov/16723203","citation_count":17,"is_preprint":false},{"pmid":"16258173","id":"PMC_16258173","title":"Adenovirus-mediated gene transfer of mutated IkappaB kinase and IkappaBalpha reveal NF-kappaB-dependent as well as NF-kappaB-independent pathways of HAS1 activation.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16258173","citation_count":16,"is_preprint":false},{"pmid":"17085450","id":"PMC_17085450","title":"The anti-rheumatic gold salt aurothiomalate suppresses interleukin-1beta-induced hyaluronan accumulation by blocking HAS1 transcription and by acting as a COX-2 transcriptional repressor.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17085450","citation_count":15,"is_preprint":false},{"pmid":"31930562","id":"PMC_31930562","title":"miR-125a regulates HAS1 and inhibits the proliferation, invasion and metastasis by targeting STAT3 in non-small cell lung cancer cells.","date":"2020","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31930562","citation_count":13,"is_preprint":false},{"pmid":"31511893","id":"PMC_31511893","title":"At least two molecules of the RNA helicase Has1 are simultaneously present in pre-ribosomes during ribosome biogenesis.","date":"2019","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/31511893","citation_count":10,"is_preprint":false},{"pmid":"23301075","id":"PMC_23301075","title":"Alteration of introns in a hyaluronan synthase 1 (HAS1) minigene convert Pre-mRNA [corrected] splicing to the aberrant pattern in multiple myeloma (MM): MM patients harbor similar changes.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23301075","citation_count":8,"is_preprint":false},{"pmid":"18400745","id":"PMC_18400745","title":"Hyaluronan production in synoviocytes as a consequence of viral infections: HAS1 activation by Epstein-Barr virus and synthetic double- and single-stranded viral RNA analogs.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18400745","citation_count":7,"is_preprint":false},{"pmid":"25421996","id":"PMC_25421996","title":"Altered expression of hyaluronan, HAS1-2, and HYAL1-2 in oral lichen planus.","date":"2014","source":"Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25421996","citation_count":5,"is_preprint":false},{"pmid":"38518923","id":"PMC_38518923","title":"AβPP-tau-HAS1 axis trigger HAS1-related nuclear speckles and gene transcription in Alzheimer's disease.","date":"2024","source":"Matrix biology : journal of the International Society for Matrix Biology","url":"https://pubmed.ncbi.nlm.nih.gov/38518923","citation_count":5,"is_preprint":false},{"pmid":"40813707","id":"PMC_40813707","title":"HAS1high cancer associated fibroblasts located at the tumor invasion front zone promote oral squamous cell carcinoma invasion via ECM remodeling.","date":"2025","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/40813707","citation_count":3,"is_preprint":false},{"pmid":"38862513","id":"PMC_38862513","title":"Whole-genome sequencing identifies variants in ANK1, LRRN1, HAS1, and other genes and regulatory regions for stroke in type 1 diabetes.","date":"2024","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/38862513","citation_count":2,"is_preprint":false},{"pmid":"21977277","id":"PMC_21977277","title":"HAS-1 genetic polymorphism in sporadic abdominal aortic aneurysm.","date":"2009","source":"Heart international","url":"https://pubmed.ncbi.nlm.nih.gov/21977277","citation_count":1,"is_preprint":false},{"pmid":"41695466","id":"PMC_41695466","title":"Therapeutic targeting of the AMPK-Has1 complex formation ameliorates metabolic dysfunction-associated steatohepatitis in mice.","date":"2026","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/41695466","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2024.11.29.626098","title":"4-Methyllumifrone (4-MU) can improve learning and memory after cerebral ischemia/reperfusion injury in rats","date":"2024-11-30","source":"bioRxiv","url":"https://doi.org/10.1101/2024.11.29.626098","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.02.12.637910","title":"Glucocorticoids modulate expression of perineuronal net component genes and parvalbumin during development of mouse cortical neurons","date":"2025-02-14","source":"bioRxiv","url":"https://doi.org/10.1101/2025.02.12.637910","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.02.05.636623","title":"Treatment of human oocytes with extracellular vesicles from follicular fluid during rescue in vitro maturation enhances maturation rates and modulates oocyte proteome and ultrastructure","date":"2025-02-05","source":"bioRxiv","url":"https://doi.org/10.1101/2025.02.05.636623","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.10.12.617979","title":"Critical role for the TGF-β1/mTORC1 signalling axis in defining the transcriptional identity of<i>CTHRC1</i>+ pathologic fibroblasts","date":"2024-10-14","source":"bioRxiv","url":"https://doi.org/10.1101/2024.10.12.617979","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":23786,"output_tokens":3589,"usd":0.062596},"stage2":{"model":"claude-opus-4-6","input_tokens":7070,"output_tokens":3212,"usd":0.173475},"total_usd":0.236071,"stage1_batch_id":"msgbatch_01DzrsgVgYngY1hvM3DU1yF2","stage2_batch_id":"msgbatch_01KA9b7iRzKFdhoBUT7vCvSe","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"HAS1 protein alone is sufficient to synthesize hyaluronan in vitro; the purified, FLAG-tagged HAS1 from membrane fractions synthesizes hyaluronan from UDP-GlcNAc and UDP-GlcA without additional cofactors. Site-directed mutagenesis of conserved residues in the cytoplasmic central loop domain identified distinct amino acid residues essential for GlcNAc and GlcA transfer, respectively. Additionally, HAS1 can synthesize chito-oligosaccharide when incubated with UDP-GlcNAc alone, with one residue required for hyaluronan but not chito-oligosaccharide synthesis.\",\n      \"method\": \"Recombinant protein purification, in vitro enzymatic assay, site-directed mutagenesis, in vitro transcription/translation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro activity with purified single protein, active-site mutagenesis with kinetic characterization\",\n      \"pmids\": [\"10617644\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"HAS1 requires a substantially higher cellular concentration of UDP-GlcNAc than HAS2 or HAS3 to synthesize hyaluronan. In COS-1 cells, HAS1 is nearly inactive at basal UDP-sugar levels but produces hyaluronan when UDP-GlcNAc is elevated ~10-fold by glucosamine supplementation, indicating HAS1 has the lowest substrate affinity among the three isoenzymes.\",\n      \"method\": \"Transfection of HAS isoenzymes in COS-1 cells, glucosamine supplementation, UDP-sugar quantification, hyaluronan secretion assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal approaches (substrate supplementation, glucose deprivation, comparison across cell types) in single study\",\n      \"pmids\": [\"23303191\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"HAS1, HAS2, and HAS3 form homomeric and heteromeric complexes with each other in live cells, detected in both Golgi apparatus and plasma membrane. These interactions occur primarily via the N-terminal 86-amino acid domain, with additional binding sites in C-terminal parts. HAS1 transfection reduces hyaluronan synthesis driven by HAS2 and HAS3, indicating functional cooperation. Of all homomeric complexes, HAS1 has the lowest synthetic activity.\",\n      \"method\": \"FRET in live cells, acceptor photobleaching FRET microscopy, proximity ligation assay with endogenous HAS antibodies, C-terminal deletion constructs\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal FRET and proximity ligation with endogenous proteins, domain-deletion mapping, functional consequence measured\",\n      \"pmids\": [\"25795779\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"HAS1-dependent hyaluronan coat formation on MCF-7 cell surfaces is induced by inflammatory cytokines (IL-1β, TNF-α, TGF-β) and glycemic stress (high glucose + glucosamine), and is dependent on CD44 receptor (coat removed by HA hexasaccharides or anti-CD44 antibody Hermes1). HAS1 enzymatic activity requires ER-Golgi-plasma membrane trafficking.\",\n      \"method\": \"Transfection of fluorescently tagged HAS1, immunocytochemistry, hyaluronan binding probe, hyaluronan hexasaccharide displacement assay, anti-CD44 antibody blocking\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct localization and functional blocking experiments, single lab study\",\n      \"pmids\": [\"24099991\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"IL-1β-induced HAS1 transcription in fibroblast-like synoviocytes depends on the p38 MAPK signaling pathway; hydrocortisone blocks TGF-β-induced HAS1 activation by inhibiting TGF-β-induced phosphorylation of p38 MAPK, as confirmed by Western blot. HAS1 (unlike HAS2/HAS3) is not constitutively expressed in these cells but is inducible by TGF-β and inflammatory stimuli.\",\n      \"method\": \"RT-PCR, Western blot for p38 MAPK phosphorylation, pharmacological inhibition with hydrocortisone/dexamethasone\",\n      \"journal\": \"Rheumatology (Oxford, England)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Western blot mechanistic link between hydrocortisone and p38 MAPK blocking HAS1, single lab\",\n      \"pmids\": [\"13130151\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"IL-1β activates HAS1 transcription via the NF-κB pathway in fibroblast-like synoviocytes, while TGF-β1 activates HAS1 independently of NF-κB. Overexpression of IκBα or dominant-negative IKK completely abolished IL-1β-induced HAS1 mRNA accumulation but did not affect TGF-β1-induced HAS1 or constitutive HAS2/HAS3 expression.\",\n      \"method\": \"Adenovirus-mediated gene transfer of mutated IKK and IκBα, RT-PCR, EMSA for NF-κB translocation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — adenoviral overexpression of dominant-negative constructs with multiple pathway readouts, two distinct stimuli compared\",\n      \"pmids\": [\"16258173\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"IL-1β-induced HAS1 activation in fibroblast-like synoviocytes depends on tyrosine kinase activity (not NF-κB), as leflunomide blocks IL-1β-induced HAS1 mRNA induction without interfering with NF-κB translocation (EMSA), and two tyrosine kinase inhibitors phenocopied leflunomide's selective block of HAS1 without affecting HAS2 or HAS3.\",\n      \"method\": \"RT-PCR, 14C-glucuronic acid incorporation assay, EMSA, pharmacological inhibitors (leflunomide, tyrosine kinase inhibitors), pyrimidine rescue experiments\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — enzymatic assay plus EMSA and multiple pharmacological tools converging on tyrosine kinase requirement, single lab\",\n      \"pmids\": [\"15905585\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Epstein-Barr virus specifically induces HAS1 mRNA and hyaluronan synthesis in fibroblast-like synoviocytes, with HAS2 and HAS3 unchanged. This virus-induced HAS1 activation requires both p38 MAPK and NF-κB pathways, demonstrated using chemical inhibitors of MAPK and adenoviral overexpression of mutated IKK and IκBα.\",\n      \"method\": \"Real-time RT-PCR, adenoviral dominant-negative constructs for IKK/IκBα, MAPK inhibitors, HA secretion assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pathway placement by dominant-negative constructs and pharmacological inhibition, single lab\",\n      \"pmids\": [\"18400745\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"HAS1 splice variants (Va, Vb, Vc) form heteromeric multiprotein assemblies with full-length HAS1 and with each other, relocalizing HAS1-FL from diffuse cytoskeletal-anchored locations to deeper cytoplasmic/Golgi spaces and protecting HAS1-FL from rapid turnover. HAS1-Vs synthesize HA intracellularly, and HAS1-Vc is transforming in vitro and tumorigenic in vivo as a single oncogene.\",\n      \"method\": \"Co-transfection, co-immunoprecipitation, subcellular localization by immunofluorescence, in vitro transformation assay, mouse xenograft tumorigenicity assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — Co-IP for complex formation, multiple functional assays including in vivo tumorigenicity, single lab\",\n      \"pmids\": [\"19451652\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Deficiency of Has1 in mice results in chronic joint inflammation and widespread intra-articular fibrosis following cartilage injury, with sustained elevated expression of genes in IL-17/IL-6 cytokine signaling, ECM turnover, and apoptosis pathways. Notably, Has1 ablation does not alter gross HA content in the ECM, suggesting HAS1 has a unique function in inflammatory HA matrix metabolism distinct from bulk HA production.\",\n      \"method\": \"Has1 knockout mouse model, cartilage debridement injury, histology, macroscopic imaging, gene expression analysis\",\n      \"journal\": \"Osteoarthritis and cartilage\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined cellular and molecular phenotype, multiple readouts, single lab\",\n      \"pmids\": [\"26521733\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Phosphorylated tau mediates AβPP-induced cytosolic-to-nuclear translocation of HAS1. P-tau negatively regulates HAS1 stability, monoubiquitination, and oligomerization, reducing HA synthesis and release. Non-ubiquitinated HAS1 loses enzymatic activity and translocates to the nucleus, forming nuclear speckles with a regulatory role in gene transcription.\",\n      \"method\": \"AβPP/PS1 mouse model, cell transfection, immunofluorescence localization, ubiquitination assays, HAS1 mutant (non-ubiquitinatable) functional analysis, transcriptomic analysis\",\n      \"journal\": \"Matrix biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — multiple methods including mutant analysis and mouse model, single lab, novel finding\",\n      \"pmids\": [\"38518923\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"AMPK physically interacts with HAS1 to form a complex in hepatocytes; disruption of this AMPK/Has1 interaction by elemicin ameliorates hepatic steatosis, inflammation, and fibrosis in MASH mice. Liver-specific inhibition of Has1 alone also ameliorates MASH phenotypes in vivo and in vitro.\",\n      \"method\": \"Co-IP, SPR binding assay, CETSA, loss-of-function (liver-specific Has1 inhibition), HFHC diet MASH mouse model, transcriptomic and lipidomic analyses\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — SPR and CETSA confirm direct AMPK-Has1 interaction, loss-of-function in vivo, single lab\",\n      \"pmids\": [\"41695466\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"STAT3 directly binds to the HAS1 promoter region to regulate HAS1 transcription in non-small cell lung cancer cells; miR-125a suppresses STAT3 expression (validated by dual-luciferase reporter assay), which in turn reduces HAS1 expression at both mRNA and protein levels.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP) assay, dual-luciferase reporter assay, RT-qPCR, Western blot, miRNA overexpression\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP confirms STAT3 binding to HAS1 promoter, luciferase confirms miR-125a targeting STAT3, single lab\",\n      \"pmids\": [\"31930562\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"HAS1 is a plasma membrane-localized hyaluronan synthase that alone can synthesize hyaluronan from UDP-GlcNAc and UDP-GlcA via conserved cytoplasmic loop residues, requires higher substrate (UDP-GlcNAc) concentrations than HAS2/HAS3, forms homo- and heteromeric complexes with other HAS isoenzymes primarily through its N-terminal domain to functionally modulate total HA output, is transcriptionally activated by IL-1β via NF-κB and by TGF-β via NF-κB-independent pathways (both requiring p38 MAPK), is regulated by STAT3 binding to its promoter, physically interacts with AMPK in hepatocytes, and undergoes ubiquitination-dependent control of its enzymatic activity and subcellular localization (including p-tau-induced nuclear translocation in Alzheimer's disease context).\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"HAS1 is a hyaluronan synthase that catalyzes the polymerization of hyaluronan from UDP-GlcNAc and UDP-GlcA at the plasma membrane, operating with lower substrate affinity than the paralogous enzymes HAS2 and HAS3 and thus functioning primarily under conditions of elevated UDP-sugar availability [PMID:10617644, PMID:23303191]. HAS1 forms homo- and heteromeric complexes with other HAS isoenzymes through its N-terminal domain, modulating total hyaluronan output, and its enzymatic activity is controlled by monoubiquitination, the loss of which triggers nuclear translocation and transcriptional regulatory functions [PMID:25795779, PMID:38518923]. Transcription of HAS1 is inducible rather than constitutive: IL-1β activates HAS1 via NF-κB and p38 MAPK, TGF-β acts through p38 MAPK independently of NF-κB, and STAT3 directly binds the HAS1 promoter [PMID:16258173, PMID:13130151, PMID:31930562]. In vivo, Has1 deficiency causes chronic joint inflammation and fibrosis following cartilage injury without altering bulk hyaluronan content, indicating a specialized role in inflammatory extracellular matrix homeostasis distinct from bulk hyaluronan production [PMID:26521733].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Establishing that HAS1 alone is sufficient for hyaluronan synthesis resolved whether the enzyme requires cofactors or additional subunits, and mutagenesis of the central cytoplasmic loop identified distinct residues for GlcNAc and GlcA transfer, defining a two-site catalytic mechanism.\",\n      \"evidence\": \"Purified recombinant FLAG-HAS1 reconstituted in vitro; site-directed mutagenesis with kinetic assays\",\n      \"pmids\": [\"10617644\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No structural model of the active site or polymer translocation mechanism\",\n        \"Chito-oligosaccharide synthesis activity observed in vitro but physiological relevance unknown\",\n        \"Lipid/membrane dependence of activity not dissected\"\n      ]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identifying p38 MAPK as required for both IL-1β- and TGF-β-induced HAS1 transcription placed the gene under inflammatory signaling control and explained how glucocorticoids selectively suppress HAS1 without affecting HAS2/HAS3.\",\n      \"evidence\": \"RT-PCR and Western blot for p38 phosphorylation in fibroblast-like synoviocytes treated with hydrocortisone and pathway inhibitors\",\n      \"pmids\": [\"13130151\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Precise p38 MAPK targets on HAS1 promoter not mapped\",\n        \"Glucocorticoid receptor mechanism of p38 inhibition not resolved\"\n      ]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Demonstrating that IL-1β induces HAS1 via NF-κB whereas TGF-β1 does so independently of NF-κB established that two major inflammatory pathways converge on HAS1 through distinct transcriptional mechanisms, and an additional tyrosine kinase requirement for IL-1β-driven HAS1 was identified.\",\n      \"evidence\": \"Adenoviral dominant-negative IKK/IκBα, EMSA, tyrosine kinase inhibitors in fibroblast-like synoviocytes\",\n      \"pmids\": [\"16258173\", \"15905585\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Identity of the required tyrosine kinase not determined\",\n        \"Promoter elements mediating NF-κB versus TGF-β responses not mapped\"\n      ]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Showing that Epstein-Barr virus selectively induces HAS1 (not HAS2/HAS3) through both p38 MAPK and NF-κB extended the inflammatory induction paradigm to viral stimuli and reinforced HAS1's role as the inducible isoenzyme.\",\n      \"evidence\": \"Real-time RT-PCR, dominant-negative IKK/IκBα adenoviral constructs, MAPK inhibitors, HA secretion assay in synoviocytes\",\n      \"pmids\": [\"18400745\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Viral component(s) triggering HAS1 induction not identified\",\n        \"Physiological consequence of virus-induced HAS1 on HA matrix not tested in vivo\"\n      ]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Discovery that HAS1 splice variants form heteromeric complexes with full-length HAS1, alter its subcellular localization, protect it from degradation, and that one variant (HAS1-Vc) acts as a single oncogene revealed a layer of post-transcriptional regulation with direct disease relevance.\",\n      \"evidence\": \"Co-IP, immunofluorescence, in vitro transformation assay, mouse xenograft tumorigenicity\",\n      \"pmids\": [\"19451652\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Mechanism of HAS1-Vc oncogenic activity not elucidated\",\n        \"Endogenous expression levels and splicing regulation of HAS1 variants poorly characterized\",\n        \"Not independently replicated in a second laboratory\"\n      ]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Quantifying HAS1's requirement for ~10-fold higher UDP-GlcNAc than HAS2/HAS3 explained why HAS1 is nearly inactive under basal metabolic conditions and linked its activity to nutrient/glycemic status.\",\n      \"evidence\": \"HAS isoenzyme transfection in COS-1 cells with glucosamine supplementation and UDP-sugar quantification\",\n      \"pmids\": [\"23303191\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Km values for purified HAS1 versus HAS2/HAS3 not compared in a cell-free system\",\n        \"Structural basis for differential substrate affinity unknown\"\n      ]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"FRET and proximity ligation demonstrated that HAS1 forms homo- and heteromeric complexes with HAS2/HAS3 at the plasma membrane and Golgi, primarily via the N-terminal 86 residues, and that HAS1 reduces HAS2/HAS3-driven HA synthesis, establishing oligomerization as a mechanism for tuning total HA output.\",\n      \"evidence\": \"Acceptor photobleaching FRET, proximity ligation assay with endogenous antibodies, C-terminal deletion mapping in live cells\",\n      \"pmids\": [\"25795779\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Stoichiometry and structural basis of HAS oligomers unresolved\",\n        \"Whether heteromeric complexes form in all tissue contexts unknown\"\n      ]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Has1 knockout mice developed chronic joint inflammation and fibrosis after cartilage injury without changes in bulk HA content, revealing a unique role for HAS1 in inflammatory matrix homeostasis distinct from overall HA production.\",\n      \"evidence\": \"Has1 KO mouse, cartilage debridement injury, histology, gene expression profiling\",\n      \"pmids\": [\"26521733\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether the phenotype is due to loss of specific HA size classes or non-HA functions of HAS1 is unknown\",\n        \"Has1/Has2 or Has1/Has3 double knockout not examined\"\n      ]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"ChIP confirmation that STAT3 directly binds the HAS1 promoter added a third transcription factor (beyond NF-κB and p38-dependent factors) to HAS1 regulation and connected HAS1 to oncogenic STAT3 signaling in lung cancer.\",\n      \"evidence\": \"ChIP assay, dual-luciferase reporter for miR-125a–STAT3 axis, RT-qPCR and Western blot in NSCLC cells\",\n      \"pmids\": [\"31930562\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Specific STAT3 binding site on HAS1 promoter not mapped at base-pair resolution\",\n        \"Functional consequence of STAT3-driven HAS1 on HA synthesis in lung cancer not quantified\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Demonstrating that phosphorylated tau destabilizes HAS1 monoubiquitination, abolishes enzymatic activity, and triggers cytosol-to-nuclear translocation where HAS1 forms nuclear speckles with transcriptional regulatory capacity revealed a non-canonical nuclear function for HAS1 in the Alzheimer's disease context.\",\n      \"evidence\": \"AβPP/PS1 mouse model, ubiquitination assays, non-ubiquitinatable HAS1 mutants, immunofluorescence, transcriptomics\",\n      \"pmids\": [\"38518923\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Target genes regulated by nuclear HAS1 not defined\",\n        \"Whether nuclear HAS1 retains any enzymatic activity is untested\",\n        \"Findings from a single laboratory and not yet independently confirmed\"\n      ]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Identification of a direct physical AMPK–HAS1 interaction in hepatocytes, whose disruption ameliorates MASH, revealed HAS1 as a metabolic effector in the liver linking HA metabolism to steatosis and fibrosis.\",\n      \"evidence\": \"Co-IP, SPR, CETSA for direct binding; liver-specific Has1 inhibition in HFHC diet MASH mouse model\",\n      \"pmids\": [\"41695466\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether AMPK phosphorylates HAS1 or modulates its activity directly is unknown\",\n        \"Mechanism by which HAS1 promotes hepatic steatosis and fibrosis not fully elucidated\",\n        \"Single laboratory finding requiring independent replication\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis for HAS1's low substrate affinity, the identity of target genes regulated by nuclear HAS1, the molecular mechanism by which ubiquitination controls HAS1 localization and activity, and whether HAS1's role in joint inflammation reflects production of specific HA size classes or non-enzymatic functions.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No crystal or cryo-EM structure of any HAS isoenzyme\",\n        \"Nuclear HAS1 transcriptional targets undefined\",\n        \"HA size-class specificity of HAS1 versus HAS2/HAS3 not resolved in vivo\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [10]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [2, 3]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [2, 8]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [10]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [0, 1, 9]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [5, 7, 12]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [5, 7]}\n    ],\n    \"complexes\": [\n      \"HAS homo/heteromeric complexes (HAS1–HAS1, HAS1–HAS2, HAS1–HAS3)\"\n    ],\n    \"partners\": [\n      \"HAS2\",\n      \"HAS3\",\n      \"STAT3\",\n      \"PRKAA1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}